AU2014363643B2 - A peptide mixture - Google Patents

A peptide mixture Download PDF

Info

Publication number
AU2014363643B2
AU2014363643B2 AU2014363643A AU2014363643A AU2014363643B2 AU 2014363643 B2 AU2014363643 B2 AU 2014363643B2 AU 2014363643 A AU2014363643 A AU 2014363643A AU 2014363643 A AU2014363643 A AU 2014363643A AU 2014363643 B2 AU2014363643 B2 AU 2014363643B2
Authority
AU
Australia
Prior art keywords
peptide
amino acid
ras protein
mixture
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014363643A
Other languages
English (en)
Other versions
AU2014363643A1 (en
Inventor
Jon Amund Eriksen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targovax Solutions AS
Original Assignee
Targovax Solutions AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Solutions AS filed Critical Targovax Solutions AS
Publication of AU2014363643A1 publication Critical patent/AU2014363643A1/en
Application granted granted Critical
Publication of AU2014363643B2 publication Critical patent/AU2014363643B2/en
Priority to AU2019201937A priority Critical patent/AU2019201937B2/en
Assigned to Targovax Solutions AS reassignment Targovax Solutions AS Request for Assignment Assignors: TARGOVAX ASA
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AU2014363643A 2013-12-09 2014-12-09 A peptide mixture Ceased AU2014363643B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019201937A AU2019201937B2 (en) 2013-12-09 2019-03-20 A peptide mixture

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13196333.2 2013-12-09
EP13196333 2013-12-09
PCT/EP2014/077033 WO2015086590A2 (en) 2013-12-09 2014-12-09 A peptide mixture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201937A Division AU2019201937B2 (en) 2013-12-09 2019-03-20 A peptide mixture

Publications (2)

Publication Number Publication Date
AU2014363643A1 AU2014363643A1 (en) 2016-07-14
AU2014363643B2 true AU2014363643B2 (en) 2019-01-03

Family

ID=49765823

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014363643A Ceased AU2014363643B2 (en) 2013-12-09 2014-12-09 A peptide mixture
AU2019201937A Ceased AU2019201937B2 (en) 2013-12-09 2019-03-20 A peptide mixture

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019201937A Ceased AU2019201937B2 (en) 2013-12-09 2019-03-20 A peptide mixture

Country Status (24)

Country Link
US (4) US9775892B2 (https=)
EP (5) EP3079715B1 (https=)
JP (2) JP6781403B2 (https=)
KR (1) KR20160097290A (https=)
CN (1) CN105980403A (https=)
AU (2) AU2014363643B2 (https=)
BR (1) BR112016013138A2 (https=)
CA (1) CA2933126A1 (https=)
CL (4) CL2016001405A1 (https=)
CY (1) CY1120578T1 (https=)
DK (1) DK3079715T3 (https=)
ES (1) ES2682038T3 (https=)
HR (1) HRP20181213T1 (https=)
HU (1) HUE039840T2 (https=)
IL (1) IL246007B2 (https=)
LT (1) LT3079715T (https=)
MX (1) MX2016007429A (https=)
PL (1) PL3079715T3 (https=)
PT (1) PT3079715T (https=)
RS (1) RS57623B1 (https=)
RU (1) RU2016127327A (https=)
SG (2) SG10201811172PA (https=)
SI (1) SI3079715T1 (https=)
WO (1) WO2015086590A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6781403B2 (ja) 2013-12-09 2020-11-04 タルゴバックス エーエスエー ペプチド混合物
US9757439B2 (en) 2014-05-06 2017-09-12 Targovax Asa Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
BR112019015797A2 (pt) * 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
EP3641807A4 (en) * 2017-06-22 2021-04-21 The Westmead Institute For Medical Research Adoptive t cell therapy 2
MX2020014243A (es) * 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN112912387A (zh) * 2018-08-22 2021-06-04 弗雷德哈钦森癌症研究中心 靶向kras或her2抗原的免疫疗法
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
JP7668226B2 (ja) * 2019-03-30 2025-04-24 ビオンテック ユーエス インコーポレイテッド Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用
WO2021009633A1 (en) * 2019-07-12 2021-01-21 Massey University Synthetic chromatin vaccine
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
KR102515083B1 (ko) 2020-12-24 2023-03-29 부산대학교 산학협력단 폴더블 페로브스카이트 태양전지 및 이의 제조 방법
CN116867799A (zh) * 2021-02-10 2023-10-10 上海吉倍生物技术有限公司 Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023220434A2 (en) * 2022-05-12 2023-11-16 The Johns Hopkins University Neoantigen vaccines for cancer prevention
EP4622664A1 (en) * 2022-11-22 2025-10-01 Elixirgen Therapeutics, Inc. Antigens for cancer immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
KR101455222B1 (ko) 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
JP6781403B2 (ja) 2013-12-09 2020-11-04 タルゴバックス エーエスエー ペプチド混合物
US9757439B2 (en) 2014-05-06 2017-09-12 Targovax Asa Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUNGER R E ET AL, "Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant.", EXPERIMENTAL DERMATOLOGY JUN 2001, (2001-06), vol. 10, no. 3, p 161 - 167 *
I. A. PRIOR ET AL, "A Comprehensive Survey of Ras Mutations in Cancer", CANCER RESEARCH, (2012-05-14), vol. 72, no. 10, doi:10.1158/0008-5472.CAN-11-2612, ISSN 0008-5472, pages 2457 - 2467 *
MARIANNE K. GJERTSEN ET AL, , INTERNATIONAL JOURNAL OF CANCER, (2001-05-01), vol. 92, no. 3, p 441 - 450 *
SYNNE WEDÉN ET AL, "Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras", INTERNATIONAL JOURNAL OF CANCER, (2010-05-12), vol. 128, no. 5, pages 1120 - 1128 *

Also Published As

Publication number Publication date
HUE039840T2 (hu) 2019-02-28
CL2018000238A1 (es) 2018-06-22
EP3079715B1 (en) 2018-06-13
EP3079715A2 (en) 2016-10-19
HRP20181213T1 (hr) 2018-10-19
BR112016013138A2 (pt) 2018-01-16
IL246007A (en) 2016-07-31
CL2016001405A1 (es) 2017-03-24
CL2018000232A1 (es) 2018-06-22
US20160331820A1 (en) 2016-11-17
CL2018000226A1 (es) 2018-06-22
AU2019201937A1 (en) 2019-04-11
EP3363457A1 (en) 2018-08-22
ES2682038T3 (es) 2018-09-18
SG11201604644QA (en) 2016-07-28
AU2019201937B2 (en) 2020-05-28
WO2015086590A3 (en) 2015-07-30
JP2017502081A (ja) 2017-01-19
IL246007B2 (en) 2023-05-01
SI3079715T1 (en) 2018-08-31
US10335473B2 (en) 2019-07-02
US10596239B2 (en) 2020-03-24
CY1120578T1 (el) 2019-07-10
MX2016007429A (es) 2016-11-11
DK3079715T3 (en) 2018-09-17
IL246007B1 (en) 2023-01-01
KR20160097290A (ko) 2016-08-17
US20180021419A1 (en) 2018-01-25
US9775892B2 (en) 2017-10-03
US20170326218A1 (en) 2017-11-16
CA2933126A1 (en) 2015-06-18
EP3357505A1 (en) 2018-08-08
RU2016127327A (ru) 2018-01-23
CN105980403A (zh) 2016-09-28
PL3079715T3 (pl) 2018-11-30
WO2015086590A2 (en) 2015-06-18
PT3079715T (pt) 2018-08-02
EP3363458A2 (en) 2018-08-22
JP2020023525A (ja) 2020-02-13
EP3363458A3 (en) 2018-11-07
JP6781403B2 (ja) 2020-11-04
AU2014363643A1 (en) 2016-07-14
US10456457B2 (en) 2019-10-29
SG10201811172PA (en) 2019-01-30
LT3079715T (lt) 2018-08-27
US20170189515A1 (en) 2017-07-06
RS57623B1 (sr) 2018-11-30
EP3369432A1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
AU2019201937B2 (en) A peptide mixture
US20190374628A1 (en) Mutated fragments of the ras protein
JP5787752B2 (ja) 抗腫瘍免疫療法
JP2023517534A (ja) Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質および抗癌剤を含む癌治療用薬学組成物
EP3840767A1 (en) Peptides
WO2021239980A2 (en) A peptide cocktail
CN103965360A (zh) Ny-eso-1抗原及其在肿瘤免疫治疗中的应用
Botta et al. New Immunotherapy Approaches for Preventing Cancer
WO2024052542A2 (en) A peptide cocktail
Rosenthal et al. Present strategies for gene therapy in cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TARGOVAX SOLUTIONS AS

Free format text: FORMER OWNER(S): TARGOVAX ASA